



Sundar Ramanan, PhD, USA

- Director, Global R & D and Regulatory Policy,
Amgen Inc, USA



Biologicals and biosimilars – totality of evidence

Sundar Ramanan, PhD

23 July 2017



Pioneering science delivers vital medicines™

Biologicals and biosimilars – the complexity of structure and function

Sundar Ramanan, PhD

Director, Policy - R&D and Regulatory Affairs

Amgen Inc.

GaBI ASEAN SBP Workshop, July 23rd 2017, Bangkok, Thailand

Discussion Topics

- Overview of biosimilar development
- Elements and limitations of analytical studies
- Role of structure-function studies



Discussion Topics

- Overview of biosimilar development
- Elements and limitations of analytical studies
- Role of structure-function studies

Biosimilar development proceeds through a stepwise similarity exercise



Approval is Based on the “Totality of Evidence”¹




Food and Drug Administration. <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf>. Accessed 24 January 2013.

Process design and analytical studies form the foundation of biosimilar development




Before non-clinical and clinical testing can proceed:

- Define the target quality profile
- Design the process
- Compare structural and functional attributes



- Use state-of-the-art analytical characterization and functional assays to assess any structural difference
- Understand the importance and limitation of functional assays


Biologics may have 4 orders of structure plus modifications that affect in vivo characteristics



[Image Source: Tim Osslund; Amgen Usage Rights: Unlimited world-wide usage rights for an unlimited time;
http://kvhs.nbed.nh.ca/gallant/biology/protein_structure.html.
Data source: USP-NF 1045. Biotechnology-derived articles: 3-20]

Biological products have very complex structures

Monoclonal antibody



Glycan modifications

- G0, G1, G2
- Core fucosylation
- High mannose
- etc

Peptide modifications

- Deamidation
- Succinimide
- Oxidation
- N & C-terminal variants
- Amino acid substitution
- Disulfide isoforms


Folding/Size

- Truncation
- Half molecules
- Dimer
- Multimers
- Aggregates
- Particles

Figure adapted from D. Kelner (Amgen), "Comparability and Biosimilarity: Two Sides of the Same (or a Different) Coin?" presented at IBC Analytical Technologies, San Diego, CA (March 2012)

Typical analytical similarity assessment evaluates 90 to 100 unique attributes

Results from a wide breadth of assay combinations compares the analytical “footprint” of the biosimilar to the reference product.



Is it possible to “match” all attributes?

Figure adapted from J. Liu et al. (Amgen), "Analytical Similarity Assessment of Biosimilars" presented at the Spring ACS Meeting, Dallas, TX (March 2014)

Biosimilar development can use a Quality-by-Design (QbD) approach

QbD for biosimilars

- Assess criticality based on literature & experience
- Characterize reference product quality attributes
- Design biosimilar to minimize differences for high criticality attributes
- Assess potential clinical relevance of remaining differences




Figure adapted from G. Grampp (Amgen), “Challenges of Structure-Function Studies for Assessing Similarity” presented at the Spring ACS Meeting, New Orleans, LA (April 2013)

Discussion Topics

- Overview of biosimilar development
- Elements and limitations of analytical studies
- Role of structure-function studies


Analytical studies should assess several aspects of structure

- Primary structure (sequence and linkages)
- Higher order structures (folding, aggregates)
- Covalent modifications (glycosylation and chemical modifications)
- Impurities (product and process)
- Stability profile

Biosimilar product should have identical amino acid sequence to the innovator

Peptide mapping

- 100% sequence confirmation
- Search for any low level amino acid substitution (sequence variant) due to translational errors, misincorporation, or mutation
- Post-translational modifications, such as glycosylation, acetylation, sulfation, phosphorylation, glycation, etc



Amgen unpublished data


Figure adapted from J. Liu (Amgen), "Analytical Testing and Characterization of Biosimilars" presented at the Health Canada SEB/Biosimilar Scientific Forum, Ottawa, Canada (November 2013)

Primary structure and covalent modifications can be assessed to high fidelity

Mass spectroscopy combined with separation based methods can address many uncertainties

- Amino acid sequences confirmed to ~100% coverage
- Covalent modifications, sequence variants and glycan structures detected to <1% resolution


Example: LC ESI MS/MS



Advanced mass spectrometry methods still leave some uncertainties

Examples of some remaining challenges

- Accurate quantitation of minor species
- Identifying and quantifying disulfide bonding patterns
- Accounting for combinatorial effects



Stable Isotope Labeled Internal Standard (SILIS)

Figures courtesy of Jiang et al, PEGS 2011

Correctly folded



Disulfide misfolds 1 and 2




Figure adapted from G. Grampp (Amgen), "Analytical Similarity Assessments" presented at the DIA/FDA Biosimilars Conference, Washington DC (September 2012)

Higher order structure and size variants are characterized by orthogonal methods





Figure adapted from J. Liu (Amgen), "Analytical Testing and Characterization of Biosimilars" presented at the Health Canada SEB/Biosimilar Scientific Forum, Ottawa, Canada (November 2013)

A common limitation of spectroscopic methods is sensitivity to mixtures

Eg, unfolded protein spiked into product

- Limit of detection is 8% by near UV circular dichroism
- How sensitive to partially unfolded species?




Amgen unpublished data

Figure adapted from G. Grampp (Amgen), "Analytical Similarity Assessments" presented at the DIA/FDA Biosimilars Conference, Washington DC (September 2012)

Particulate characterization technology is improving

- Focus on characterizing particles (0.1 μm to 10 μm)
 - Size, composition, quantity, structure
 - Relevance to immunogenicity
- Improving sensitivity, accuracy, and specificity
 - Protein vs. container
 - Emerging nanotechnology-based approaches for $< 1 \mu\text{m}$ particles
- Quantitative and qualitative comparisons remain difficult

Aggregation ($<0.1 \mu\text{m}$)




Particulation ($>1 \mu\text{m}$)

MFI



Light obscuration




Amgen unpublished data

AMGEN

Figure adapted from G. Grampp (Amgen), "Analytical Similarity Assessments" presented at the DIA/FDA Biosimilars Conference, Washington DC (September 2012)

Glycosylation is a critical quality attribute that can impact biological functions



Amgen unpublished data

Glycan mapping by HILIC and Mass Spectrometry

- Over 25 mAb glycans identified
- Correlate glycan attributes with biological function

Glycan Type	Impact to function
No glycan	No ADCC
Bisecting GN	Increase ADCC
High mannose	Clearance and effector function
Terminal Gal	Increase CDC
NANA	Anti-inflammatory
Afucosylated	Increase ADCC

Product isoforms need to be fully characterized using separation methods


Size variants

- Truncation
- Dimer
- Multimers


Charge and hydrophobic variants

- N-terminal modification
- C-terminal modification
- Deamidation
- Oxidation

Size Exclusion HPLC



Isoelectric Focusing



Ion Exchange HPLC






Figure adapted from J. Liu (Amgen), "Analytical Testing and Characterization of Biosimilars" presented at the Health Canada SEB/Biosimilar Scientific Forum, Ottawa, Canada (November 2013)

Separation methods also used to examine the integrity of covalent structure



Non-reducing SDS

- Partial molecules
- Half molecules
- Fragments
- Non-disulfide linked aggregates



Reducing SDS

- Truncation
- Clipped species


Figure adapted from J. Liu (Amgen), "Analytical Testing and Characterization of Biosimilars" presented at the Health Canada SEB/Biosimilar Scientific Forum, Ottawa, Canada (November 2013)

Product-related and process-related impurities must be well characterized

- High resolution and orthogonal methods are required to characterize product-related species.


Size variants:

- Truncation
- Dimer
- Multimers
- Clipped species
- Non-disulfide linked aggregates
- Partial molecules
- Half molecules
- Fragments
- Non-disulfide linked aggregates



Charge and Hydrophobic Variants:

- N-terminal modification
- C-terminal modification
- Deamidation
- Oxidation




- Process-related impurities (HCP, DNA, leachables, etc) need to be characterized to ensure product quality.
- Particles and aggregates of various sizes need to be evaluated and characterized.

Figure adapted from J. Liu et al. (Amgen), "Analytical Similarity Assessment of Biosimilars" presented at the Spring ACS Meeting, Dallas, TX (March 2014)

Proteins undergo complex degradation and are sensitive to storage and handling

Biosimilar stability is impacted by its manufacturing process and formulation




Degradation contributes to eventual loss of biological activity and/or potential immunogenicity

Figure adapted from J. Liu (Amgen), "Analytical Testing and Characterization of Biosimilars" presented at the Health Canada SEB/Biosimilar Scientific Forum, Ottawa, Canada (November 2013)

Forced degradation studies should demonstrate similar stability profiles

Multiple accelerated thermal stress conditions (25, 40, 50°C) provide a quantitative, reproducible, and sensitive comparison of degradation profiles and rates

- Example: Size Exclusion Chromatography profiles – 50°C, T=15 days



- Rate comparisons: 0-15 days




Figure adapted from J. Liu et al. (Amgen), "Analytical Similarity Assessment of Biosimilars" presented at the Spring ACS Meeting, Dallas, TX (March 2014)

Discussion Topics

- Overview of biosimilar development
- Elements and limitations of analytical studies
- Role of structure-function studies

Structural comparisons leave residual uncertainties

Sources of uncertainty	Potential consequences
Assay limitations (limit of detection, specificity, etc.)	Unobserved differences could potentially impact efficacy or safety
Lot to lot variability and population statistics	Equivalence of means does not prove that individual lots are biologically equivalent
Observed differences in critical attributes	Could impact safety or efficacy if differences are large enough
Observed differences in less critical attributes	<ul style="list-style-type: none">• Are assumptions about criticality correct?• Could combinations of attributes become significant?

Functional studies are the first step in addressing these residual uncertainties

Why functional characterization?

Part 1: Required by regulators


- Functional characterization required
 - To confirm quality and potency of the product
 - To address limitations of structural assays
 - To confirm similar mechanism(s) of action
 - presence of expected function, absence of new function
 - specificity of target binding
- *Relevant passage from FDA guidance*

*“Depending on the structural complexity of the protein and available analytical technology, the **physicochemical analysis may be unable to confirm the integrity of the higher order structures**. Instead, the integrity of such structures can be inferred from the product’s biological activity.” (Emphasis added)*



FDA Draft Guidance, Quality Considerations in Demonstrating Biosimilarity to a Reference Product, February 2012

Figure adapted from G. Grampp (Amgen), “Challenges of Structure-Function Studies for Assessing Similarity” presented at the Spring ACS Meeting, New Orleans, LA (April 2013)

Matching all biological and functional properties is essential



Amgen unpublished data



4-P Fit: $y = (A - D) / (1 + (x/C)^B) + D$

	A	B	C	D	R ²
EU Lot H0134B01 - (H0134B01: Concentr...	1.65e+06	1.31	49.4	-4.43e+04	0.997
EU Lot H0021B06 - (H0021B06: Concentr...	1.64e+06	1.38	73.9	-4.51e+04	0.998
EU Lot H0138B01 - (H0138B01: Concentr...	1.63e+06	1.38	65	-4.21e+04	0.997
ABP Lot 0010095534 - (GMP1 0010095534: ...	1.68e+06	1.29	62.9	-5.2e+04	0.998
ABP Lot 0010112870 - (GMP2 0010112870: ...	1.62e+06	1.43	71	-4.68e+04	0.992
ABP Lot 0010133673 - (GMP3 0010133673: ...	1.64e+06	1.53	64.9	-3.38e+04	0.997
US Lot 970032 - (970032: Concentr...	1.63e+06	1.41	74.4	-3.61e+04	0.998
US Lot 450657 - (450657: Concentr...	1.64e+06	1.31	79.2	-5.64e+04	0.998
US Lot 450657 - (450657: Concentr...	1.64e+06	1.31	79.2	-5.64e+04	0.998

Biological functions are dependent on the target antigen

Figure adapted from J. Liu et al. (Amgen), presented at the Spring ACS Meeting, Dallas, TX (March 2014)

Why functional characterization?

Part 2: May be essential to justify differences

QbD for biosimilars

- Assess criticality based on literature & experience (where available)
- Minimize differences for high criticality attributes
- Perform structure-function studies to assess remaining differences
- Relate findings to potential clinical impact





Figure adapted from G. Grampp (Amgen), “Challenges of Structure-Function Studies for Assessing Similarity” presented at the Spring ACS Meeting, New Orleans, LA (April 2013)


Prepared samples can increase sensitivity of structure-function studies



Notional data for illustration purposes only

Figure adapted from G. Grampp (Amgen), "Challenges of Structure-Function Studies for Assessing Similarity" presented at the Spring ACS Meeting, New Orleans, LA (April 2013)

Cation exchange profile of a mAb



Charge Variants	% Relative Potency
Acidic variants	82
Main peak	101
Basic variants	84

Amgen unpublished data

Improved estimate of slope informs potential criticality and permitted magnitude of differences

Studies must provide relevant conclusions


1) Evaluate in vitro functional data

- a) Test functional equivalence of actual batches

Is a 25% difference *really* acceptable?


- b) Relate attribute difference to parameters from structure–function studies

- Measured difference in means
- Estimated quantitative effect
- Relate to clinically meaningful differences



Attribute Level

Notional data for illustration purposes only



Notional data for illustration purposes only

Figure adapted from G. Grampp (Amgen), "Challenges of Structure-Function Studies for Assessing Similarity" presented at the Spring ACS Meeting, New Orleans, LA (April 2013)

Studies must provide relevant conclusions

2) Evaluate PK and drug metabolism where feasible

- Serum incubation in vitro: is a variant formed under physiologic conditions?
- Product recovery from PK samples

In vivo vs. in vitro
conversion of Glu to pyroGlu





Figure adapted from G. Grampp (Amgen), "Challenges of Structure-Function Studies for Assessing Similarity" presented at the Spring ACS Meeting, New Orleans, LA (April 2013)

Small effects can combine in unexpected ways

Process change case study

- Change resulted in shifts in 2 attributes (see figure)
- Bioassays predicted equivalent potency
- Equivalent PK shown in human clinical study
- Potency difference detected in clinical PD study
- Post hoc studies with prepared fractions identified additive effects on potency

In vitro potency of prepared fractions




Figure adapted from G. Grampp (Amgen), "Challenges of Structure-Function Studies for Assessing Similarity" presented at the Spring ACS Meeting, New Orleans, LA (April 2013)

Amgen unpublished data


Additional challenges in structure-function studies

- Predicting human PK/PD
 - Animal studies may not account for species specific clearance mechanisms
 - Insufficient power due to small number of animals
- Predicting human immune response
 - In silico, in vitro, and in vivo methods are insufficient to rule-out clinically relevant differences

Summary and Conclusions



- Analytical advances permit high resolution similarity assessments for many attributes
 - Higher order structure and particle assessments still subject to uncertainty
 - Orthogonal approaches partially compensate for lower sensitivity
- Assessing impact of differences remains challenging
 - Not all clinically relevant effects can be evaluated pre-clinically (e.g., PK and immunogenicity)
 - Small effects and combinations difficult to assess

Biosimilar development and approval is based on the totality of evidence




- Each step uses scientific rigor and state-of-the-art capabilities
- Each step independently supports similarity and combined demonstrate a 'highly similar' product
- "Totality of evidence" approach is used for regulatory approvals

Analytical characterization is the foundation of biosimilarity demonstration



Analytical methods should be sensitive to assess protein structure and drug product characteristics




CE, capillary electrophoresis; ELISA, enzyme-linked immunosorbent assay; MS, mass spectrometry; PCR, polymerase chain reaction; S-S, disulfide.

1. Shapiro M. Advisory Committee for Pharmaceutical Science and Clinical Pharmacology Meeting. August 8, 2012. Available at:


<http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeForPharmaceuticalScienceandClinicalPharmacology/UCM315764.pdf> Accessed March 2015.

Biosimilars should match the activity (function) of the reference product¹




1. US Food and Drug Administration. Available at: <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf>. Accessed September 2015. 2. Reichert JM. *mAbs* 2011;3:223–240. 3. Peake STC et al. *Inflamm Bowel Dis* 2013;19:1546–1555.

Nonclinical Studies




US Food and Drug Administration. Available at: <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf>. Accessed September 2015.

Pharmacology: pharmacokinetics and pharmacodynamics




1. US Food and Drug Administration. Available at: <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf>. Accessed September 2015. 2. US Food and Drug Administration. Available at: <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm397017.pdf>. Accessed September 2015.

Comparative clinical safety, efficacy, and immunogenicity



Comparative clinical safety, efficacy, and immunogenicity



US Food and Drug Administration. Available at: <http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291128.pdf>. Accessed September 2015.


Extrapolation of Indications

A proposed biosimilar product may be licensed in one or more additional indications for which the reference product is licensed, if appropriate scientific justification is provided

Reference product studies



Biosimilar studies



CRC = colorectal cancer; mRCC = metastatic renal cell carcinoma; MBC = metastatic breast cancer; GBM = glioblastoma multiforme; CC = cervical cancer.

CBER. *Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry*. Silver Spring, MD: FDA. www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Published April 2015. Accessed September 27, 2015.

Extrapolation of Indications Requires Scientific Justification

Scientific Justification Should Establish

MOA in each indication*

PK, PD, and immunogenicity in different patient populations

Differences in expected toxicities in each indication

Any other factor that may affect safety or effectiveness in each indication

Health authorities may have differing perspectives on what evidence is sufficient to support extrapolation

*MOA in each indication may include target/receptors for each relevant activity/function; binding, dose/concentration of response, and pattern of molecular signaling upon engagement of target; relationship between product structure and target/receptor interactions; and location and expression of target/receptors.

CBER. *Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry*. Silver Spring, MD: FDA.

www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Published April 2015. Accessed September 27, 2015.

From a Quality Perspective, Amgen is Able to Match ~100 Critical Attributes Necessary to Show Biosimilarity

Amgen Biosimilar Attributes Compared to U.S. and EU Reference Product

Product Example

General Properties
Primary Structure
High-Order Structure
Biological
Product-Related Substances and Impurities
Process-Related Impurities
Particles and Aggregates
Thermal-Forced Degradation

	ABP vs. U.S. Reference Product	ABP vs. EU Reference Product
Attributes Matched	91	93
Attributes Not Matched but Not Critical	4	2
Attributes Not Matched and Critical	0	0

Thank you!

